Clinical trial for Non-Small Cell Lung Cancer
Official title Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
ClinicalTrials.gov ID: NCT04852588
What this study is testing
- What it's testing
- The study aims to find out if sampling suspicious chest lymph nodes with a needle provides more accurate information about disease spread than imaging alone in metastatic non‑small cell lung cancer.
- Who it's for
- Adults with advanced non‑small cell lung cancer who are scheduled for curative‑intent stereotactic ablative radiotherapy.
- What's involved
- Participants will have a needle biopsy of chest lymph nodes using an ultrasound‑guided bronchoscope (EBUS‑TFNA) or esophageal scope (EUS‑FNA), followed by the planned radiation treatment and routine follow‑up visits.
- Time commitment
- The study involves one sampling procedure and the regular radiation treatment schedule, lasting several weeks with periodic clinic visits.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5...
- Radical treatment intent to all sites is recommended at multi-disciplinary tumour board or by discussion by medical oncologist and radiation...
- Age 18 years or older
- Good performance status (Eastern Cooperative Oncology Group [ECOG 0-1) with life-expectancy of at least 6 months as determined by enrolling physician
- Patient has undergone staging investigations less than 3 months prior to registration.
You likely can't join if
- Contraindication to Endobronchial Ultrasound (EBUS) / Endoscopic Ultrasound (EUS)
- Unable to provide consent for EBUS/EUS
- Contraindication to chest radiotherapy
- Pregnant or lactating women
See the full eligibility criteria
- Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5 synchronous metastases
- Radical treatment intent to all sites is recommended at multi-disciplinary tumour board or by discussion by medical oncologist and radiation oncologist and/or surgeon.
- Age 18 years or older
- Good performance status (Eastern Cooperative Oncology Group [ECOG 0-1) with life-expectancy of at least 6 months as determined by enrolling physician
- Patient has undergone staging investigations less than 3 months prior to registration.
- Positron Emission Tomography (PET) / Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) brain (CT brain with contrast if contraindication to MRI) OR
- CT chest/abdomen, radionucleotide bone scan and MRI of brain (CT brain with contrast if contraindication to MRI)
- Pathologic confirmation of NSCLC
- Contraindication to Endobronchial Ultrasound (EBUS) / Endoscopic Ultrasound (EUS)
- Unable to provide consent for EBUS/EUS
- Contraindication to chest radiotherapy
- Pregnant or lactating women
The study team makes the final eligibility decision.
Where it is enrolling
- London, Ontario, Canada
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at London, Ontario, Canada; Toronto, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.